Jefferies Group LLC Cel Sci Corp Transaction History

Jefferies Group LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$11.05 - $16.62 $14,155 - $21,290	-1,281 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$11.69 - $14.54 $14,974 - $18,625	1,281 New	1,281 $16,000
Q4 2019 Feb 13, 2020	SELL	$6.71 - $9.55 $4,978 - $7,086	-742 Closed	0 $0
Q3 2019 Nov 13, 2019	BUY	$6.0 - $9.6 $4,452 - $7,123	742 New	742 $7,000

27.1K

150K

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $24.3M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

Get notified when there are updates to the investment portfolio of Jefferies Group LLC, based on Form 13F filings with the SEC.

Stay updated on Jefferies Group LLC with notifications on news.